^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Hensify (crystalline hafnium oxide)

    i
    Other names: JNJ1900, JNJ 1900, JNJ-90301900, NBTXR3, PEP503, PEP-503, NBTXR 3, NBTX 3, NBTXR-3, JNJ-1900
    Associations

    News

    Trials
    Company:
    J&J, LianBio, Nanobiotix
    Drug class:
    Free radical stimulant, Radiosensitiser
    Related drugs:
    Associations

    News

    Trials
    14d
    NANORAY-312: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC (clinicaltrials.gov)
    P3, N=500, Recruiting, Johnson & Johnson Enterprise Innovation Inc. | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial primary completion date
    |
    Erbitux (cetuximab) • Hensify (crystalline hafnium oxide)
    19d
    A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer (ChiCTR2600118958)
    P2, N=130, Shandong First Medical University Affiliated Tumor Hospital; Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Canc
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    Imfinzi (durvalumab) • Hensify (crystalline hafnium oxide)
    1m
    NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=40, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Hensify (crystalline hafnium oxide)
    2ms
    NCI-2020-03731: NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer (clinicaltrials.gov)
    P1, N=24, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended
    Trial suspension
    |
    Hensify (crystalline hafnium oxide)
    3ms
    90301900HNC1001: A Study of JNJ-90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC (2025-522914-22-00)
    P1, N=8, Recruiting, Janssen Cilag International
    New P1 trial
    |
    Hensify (crystalline hafnium oxide)
    3ms
    Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=40, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    Hensify (crystalline hafnium oxide)
    4ms
    NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer (clinicaltrials.gov)
    P2, N=14, Terminated, M.D. Anderson Cancer Center | Trial completion date: Sep 2026 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2026 --> Jan 2026; <75% participation
    Trial completion date • Trial termination • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Hensify (crystalline hafnium oxide)
    5ms
    LUMIRAY: A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Johnson & Johnson Enterprise Innovation Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Hensify (crystalline hafnium oxide)
    5ms
    NANORAY-312: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC (clinicaltrials.gov)
    P3, N=500, Recruiting, Johnson & Johnson Enterprise Innovation Inc. | Trial completion date: Dec 2027 --> Jun 2028
    Trial completion date
    |
    Erbitux (cetuximab) • Hensify (crystalline hafnium oxide)
    6ms
    NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=24 --> 34
    Enrollment closed • Enrollment change
    |
    Hensify (crystalline hafnium oxide)
    6ms
    NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    Hensify (crystalline hafnium oxide)
    6ms
    NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical • Hensify (crystalline hafnium oxide)